Patient-reported outcome measures in psoriasis: Assessing the assessments

British Journal of Dermatology

Volumn 172, Issue 5, 2015, Pages 1178-1179

  Finlay, A Y ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; CLINICAL EXAMINATION; CONSULTATION; DERMATOLOGY LIFE QUALITY INDEX; EDITORIAL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME MEASURE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; SELF EVALUATION; SELF REPORT; SHORT FORM 36;

HUMANS; PATIENT OUTCOME ASSESSMENT; PSORIASIS;

EID: 84929103842     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13775     Document Type: Editorial

References (15)

1. Hajjaj FM, Salek MS, Basra MKA, Finlay AY,. Nonclinical influences, beyond diagnosis and severity, on clinical decision making in dermatology: understanding the gap between guidelines and practice. Br J Dermatol 2010; 163: 789-99.
2. Harun NA, Salek S, Piguet V, Finlay AY,. The dermatology outpatient discharge decision: understanding a critical but neglected process. Br J Dermatol 2014; 170: 1029-38.
3. Kitchen H, Cordingley L, Young H, et al,. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol 2015; 172: 1210-21.
4. Chalmers JR, Schmitt J, Apfelbacher C, et al,. Report from the third international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol 2014; 171: 1318-25.
5. Cochrane Skin Group. The Cochrane Skin Group Core Outcomes Set Initiative (CSG-COUSIN). Available at: http://skin.cochrane.org/sites/skin.cochrane.org/files/uploads/Homepage-COUSIN-Vers3.pdf (last accessed 5 March 2015).
6. Gottlieb AB, Levin AA, Armstrong AW, et al,. The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol 2015; 72: 345-8.
7. DeMuro C, Clark M, Doward L, et al,. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). Value Health 2013; 16: 1150-5.
8. Finlay AY, Basra MKA, Piguet V, Salek S,. DLQI: a paradigm shift to patient-centred outcomes. J Invest Dermatol 2012; 132: 2464-5.
9. Pereira FR, Basra MKA, Finlay AY, Salek MS,. The role of EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology 2012; 225: 45-53.
10. Basra MKA, Zammit AM, Kamudoni P, et al,. PFI-14©: a Rasch analysis refinement of the Psoriasis Family Index. Dermatology 2015; in press.
11. Golics CJ, Basra MK, Finlay AY, Salek S,. The development and validation of the Family Reported Outcome Measure (FROM-16)© to assess the impact of disease on the partner or family member. Qual Life Res 2014; 23: 317-26.
12. Psoriasis360. Psoriasis360 app. Available at: www.psoriasis360.com (last accessed 5 March 2015).
13. Campbell N, Ali F, Finlay AY, Salek SS,. Equivalence of electronic and paper-based patient-reported outcome measures. Qual Life Res 2015; Feb 22, in press.
14. Hongbo Y, Thomas CL, Harrison MA, et al,. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125: 659-64.
15. Basra MK, Salek MS, Camilleri L, et al,. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27-33.